Equity Overview
Price & Market Data
Price: $9.57
Daily Change: +$0.23 / 2.40%
Range: $9.17 - $9.59
Market Cap: $925,791,232
Volume: 1,254,566
Performance Metrics
1 Week: -1.54%
1 Month: 12.19%
3 Months: 14.89%
6 Months: -4.30%
1 Year: -37.33%
YTD: -8.94%
Company Details
Employees: 188
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Ireland
Details
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.